John R. Treace to retire from board; Chairman James T. Treace reclassified as Class I director

TREACE MEDICAL CONCEPTS, INC.

John R. Treace (father of CEO) will retire at the 2022 annual meeting and not stand for re-election.
Decision not related to any disagreement with the Company's operations, policies, or disclosures.
Board approved reclassification of Chairman James T. Treace to Class I director, effective upon John R. Treace's term expiration.
James T. Treace will stand for election as a Class I Director at the 2022 Annual Meeting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John R. Treace

Director

TMCI · TREACE MEDICAL CONCEPTS, INC.

Filed: February 25, 2022, 6:59 PM ET

On February 22, 2022, John R. Treace provided notice to the board of directors (the “ Board ”) of Treace Medical Concepts, Inc. (the “ Company ”) of his intent to retire from the Board at the expiration of his current term at the 2022 annual meeting of stockholders (the “ 2022 Annual Meeting ”) and not to stand for re-election.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John R. Treace departed as director at TREACE MEDICAL CONCEPTS, INC..

Action: retire

Exact text from the filing

On February 22, 2022, John R. Treace provided notice to the board of directors (the “ Board ”) of Treace Medical Concepts, Inc. (the “ Company ”) of his intent to retire from the Board at the expiration of his current term at the 2022 annual meeting of stockholders (the “ 2022 Annual Meeting ”) and not to stand for re-election.

View on SEC.gov

TREACE MEDICAL CONCEPTS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-002108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.